newsfilter
← Latest News
GlobeNewswire·

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

  • Exagen Inc. reported full-year 2025 revenue of $66.6 million, a 20% increase compared to 2024.
  • AVISE CTD test volume grew over 11% in 2025, driven by new biomarkers & sales force expansion.
  • The trailing twelve-month average selling price (ASP) for AVISE CTD reached $441, a 7% increase from 2024.
  • The company supported care for over 137,000 patients tested by AVISE CTD in 2025.
  • Exagen launched novel T-Cell & seronegative RA biomarkers, including anti-RA33 & anti-PAD4.
  • Michael Mahler, PhD was appointed Chief Scientific Officer & Chas McKhann joined the Board of Directors.
  • The company raised capital through a $20 million public offering & a $25 million credit facility.
  • Cash, cash equivalents, & restricted cash totaled $32.4 million at the end of 2025.
  • Full-year 2025 net loss was $19.951 million, with adjusted EBITDA at $(9.794) million.
  • Exagen expects full-year 2026 revenue to range between $70 million & $73 million.
  • A conference call to discuss results is scheduled for March 10, 2026, at 8:30 a.m. ET.